The currently available anti-TNFα agents for the treatment of CD in Japan include infliximab [Remicade; Janssen Biotech Inc., Malvern, PA, USA]3 and adalimumab [Humira; AbbVie Inc., North Chicago, IL, USA].4 Here, TNF is linked to Cowden disease.